141 results
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
17 May 24
Results of Operations and Financial Condition
8:27am
salaries and related costs, clinical trial costs related to obe-cel, and a decrease in our U.K. reimbursable R&D tax credits claimable through the U.K … - (3,768) Total operating expenses, net (38,757) (39,148) Total other expenses, net (13,941) (677) Net loss before income tax (52,698) (39,825) Income
8-K
EX-99.2
AUTL
Autolus Therapeutics plc
17 May 24
Results of Operations and Financial Condition
8:27am
) (14,364) Income tax benefit 8 14 (6) Net loss after tax (52,690) (39,811) (12,879) Q1 2023 ($ '000) Q4 2023 ($ '000) Variance ($ '000) Cash and cash
S-3ASR
AUTL
Autolus Therapeutics plc
28 Mar 24
Automatic shelf registration
4:10pm
in the form of ADSs.
TAXATION
The following summary contains a description of material U.K. and U.S. federal income tax consequences … of the acquisition, ownership and disposition of our ADSs. This summary should not be considered a comprehensive description of all the tax considerations that may
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
by governments;
differing reimbursement regimes and price controls in certain non-U.S. markets;
negative consequences from changes in tax laws;
compliance … with tax, employment, immigration and labor laws for employees living or traveling abroad, including, for example, the variable tax treatment
10-K
EX-97.1
xaid y72q
21 Mar 24
Annual report
4:55pm
10-K
EX-10.12
qt25vc9 30
21 Mar 24
Annual report
4:55pm
8-K
j5hbiy
21 Mar 24
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
4:21pm
8-K/A
EX-99.1
hrxp74
15 Mar 24
Results of Operations and Financial Condition
4:21pm
8-K
EX-99.1
6bo6k6ri
14 Mar 24
Results of Operations and Financial Condition
12:32pm
8-K
EX-99.2
744i023vrhd mwa4
14 Mar 24
Results of Operations and Financial Condition
12:32pm
424B5
z0jy9r h53o6f
9 Feb 24
Prospectus supplement for primary offering
5:15pm
8-K
EX-1.1
t1xzs x7u8
8 Feb 24
Autolus Announces Pricing of Underwritten Offering
4:17pm
8-K
EX-10.1
9utrot
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
S-3ASR
EX-4.10
tbxakn7g0h52cluc8fmx
7 Feb 24
Automatic shelf registration
10:00pm
S-3ASR
p9uok 21pgp
7 Feb 24
Automatic shelf registration
10:00pm
S-3ASR
EX-4.7
jdzak wv4
7 Feb 24
Automatic shelf registration
10:00pm
S-3ASR
EX-4.9
tc7skt9tv4xt2yyitno
7 Feb 24
Automatic shelf registration
10:00pm
10-Q
137ilhikv 1geh
9 Nov 23
Quarterly report
4:18pm
10-Q
EX-10.1
g1sa2mescq innty6si
9 Nov 23
Quarterly report
4:18pm